Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFragrant Prosp. Regulatory News (FPP)

Share Price Information for Fragrant Prosp. (FPP)

Share Price is delayed by 15 minutes
Get Live Data
0.48    0.00 (0.00%)
Bid:
0.46
Ask:
0.50
Spread: 0.04 (8.696%)
Market Cap: £1.22m
FPP Live PriceLast checked at - London Stock Exchange

Intraday Fragrant Prosp. Share Chart

Appointment of Director

29 Mar 2021 07:00

RNS Number : 7338T
Fragrant Prosperity Holdings Ltd
29 March 2021
 

29 March 2021

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN, INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. 

 

Fragrant Prosperity Holdings Limited

("FPP" or the "Company")

Appointment of Director

The Board of Directors of Fragrant Prosperity Holdings Limited, which is seeking an acquisition in several sectors but is currently focused on Cannabis Therapeutics, is pleased to announce the appointment of Dr. Daniel S. Reshef, MD, MPH, PhD to the Board of Directors as a non-executive director. This appointment will become effective as of March 31, 2021.

Dr. Daniel Reshef is a dual Israeli and USA Citizen, currently living in the USA, with strong ties to Israel, Israel medical research centres and a vast array of relationships in the global pharmaceutical sector.

Dr Reshef's extensive career with over twenty five years in drug development encompasses many facets of the Pharmaceutical sector, gained through senior management positions at leading companies such as Hoffman La Roche, Genentech, Bristol Myers Squibb, and in his current capacity as the Therapeutic Area Global Head for a major global Pharmaceutical Company. His scientific experience includes skills in regulatory, medical affairs, drug safety operations and clinical trials epidemiology with leadership experience in early drug development from phase 1 to phase IV, and in multiple therapeutic areas.

Dr. Reshef is a board-certified physician, graduate of the Hebrew University and Hadassah Medical School in Jerusalem, and has earned his MPH and PhD in Epidemiology from Johns Hopkins University.

Craig Marshak Chairman of Fragrant Prosperity commented: "I have personally known and worked with Dr. Daniel Reshef for well over 7 years, and have always been impressed with his world wide experience and skill set. I am delighted to welcome him to the Board and look forward to the additional expertise that he brings to the Company"

Current and previous Directorships within the last 5 years that Dr Reshef holds are set out below:

Current

Previous 5 years

ABTI - Alterola pharmaceuticals - Director

 

QEBR - Virtual Medical - Director, Vice Chair

 

Israel Venture Partners - Director

 

 

 

 

 

 

 

 

*Ends*

 

For more information: http://www.fragrantprosperityholdings.com/

 

Fragrant Prosperity Holdings Limited

 

Simon Retter/Craig Marshak

+44 (0) 20 3137 1902

Broker: Optiva Securities

Vishal Balasingham +44 (0) 20 3137 1903

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADKCBKBBKKKNB
Date   Source Headline
28th May 202612:55 pmRNSDirector/PDMR Shareholding
1st Apr 20267:00 amRNSYear End Update
19th Jan 20267:00 amRNSHolding(s) in Company
31st Dec 20257:00 amRNSHalf-year Financial Report
31st Dec 20257:00 amRNSHalf-year Financial Report
8th Dec 20257:00 amRNSHolding(s) in Company
2nd Dec 20257:00 amRNSHolding(s) in Company
12th Nov 20257:10 amRNSHolding(s) in Company
3rd Nov 20257:00 amRNSHolding(s) in Company
31st Oct 20253:42 pmRNSHolding(s) in Company - Replacement
31st Oct 20251:40 pmRNSHolding(s) in Company
31st Oct 20251:00 pmRNSHolding(s) in Company
31st Oct 202512:22 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSHolding(s) in Company
13th Aug 20257:00 amRNSDirector/PDMR Shareholding
11th Aug 20257:00 amRNSBoard Changes
31st Jul 20257:00 amRNSFinal Results
14th Jul 202511:08 amRNSBusiness Update
11th Jul 20257:00 amRNSHolding(s) in Company
8th Jul 20257:00 amRNSHolding(s) in Company
7th Jul 20257:00 amRNSHolding(s) in Company
4th Jul 20257:01 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
2nd Jul 20257:00 amRNSHolding(s) in Company
27th Jun 202511:16 amRNSResult of AGM
25th Jun 20257:00 amRNSPublication of a Prospectus
29th May 20257:00 amRNSNotice of AGM
22nd May 20257:00 amRNSIssue of Equity
24th Apr 20254:54 pmRNSHolding(s) in Company
24th Apr 20251:24 pmRNSHolding(s) in Company
24th Apr 20251:23 pmRNSHolding(s) in Company
23rd Apr 20258:54 amRNSIssue of Equity
22nd Apr 20257:00 amRNSAppointment to Investment Advisory Board
17th Apr 20258:26 amRNSAmendment: New CLN Issued
17th Apr 20257:00 amRNSNew CLN Issued
2nd Jan 20259:27 amRNSHalf-year Report
31st Oct 20241:57 pmRNSHolding(s) in Company
12th Sep 20241:10 pmRNSHolding(s) in Company
31st Jul 20247:00 amRNSFinal Results
7th Jun 20247:30 amRNSRestoration - Fragrant Prosperity Holdings Ltd
6th Jun 20241:55 pmRNSAnnual Financial Report on NSM
30th May 20247:00 amRNSHalf-year Report
28th Mar 20247:01 amRNSFinal Results
22nd Nov 20233:00 pmRNSStatement re. Suspension
23rd Mar 202311:27 amRNSStatement re. Suspension
16th Mar 20237:01 amRNSHolding(s) in Company
16th Mar 20237:00 amRNSHolding(s) in Company
13th Mar 20237:00 amRNSHolding(s) in Company
10th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 20232:48 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.